ClinicaliQ Trial Snapshot
- MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01) — Recruiting • Phase II • Oncology • NCT06534437.
- What is being tested: MEN1703 (SEL24/Dapolsertib hydrochloride), a novel agent being evaluated as monotherapy or in combination with glofitamab, assessing safety and anti-lymphoma activity in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
- Patient eligibility overview: Adults with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma who have progressed despite prior standard treatments, representing a population with limited therapeutic options and poor prognosis.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The goal of the study is to assess the safety and anti-lymphoma activity of MEN1703 (Dapolsertib hydrochloride) when given as a single-agent or combined with glofitamab to patients with relapsed/refractory (R/R) aggressive B-cell non-Hodgkin lymphoma. The study will be open to groups at the same time: * Group 1 - patients who have not had anti-CD3xCD20 bispecific antibody therapy but who have had at least 2 prior lines of systemic treatment for aggressive B-cell non-Hodgkin lymphoma * Group 2 - patients who have exhausted all standard treatment options including at…
Eligibility Snapshot
- : 1. Age ≥18 years old 2. Documented histological confirmation of aggressive B-cell non-Hodgkin lymphoma including DLBCL NOS and transformed indolent B-cell lymphoma 3. Relapsed or refractory disease having received at least 2 prior lines of systemic treatment and, naïve to anti-CD3xCD20 bispecific antibody treatment (group 1) or exhausted all standard, available treatment options (group 2) 4. At least 1 measurable site of disease based on computed tomography (CT) or positron emission tomography (PET)-CT scan with involvement of 2 or more clearly demarcated lesions and or nodes. 5. Availability of lymph node tissue at Screening (or archival sample) (part 2 participants only) 6. Life expectancy of ≥12 weeks. 7. Eastern Cooperative Oncology Group (ECOG) Performance Status 0, 1 or 2 8. Adequate organ function at Screening 9. Adequate hematologic function
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.